Stroke in Fabry Disease Frequently Occurs Before Diagnosis and in the Absence of Other Clinical Events Natural History Data From the Fabry Registry

被引:269
作者
Sims, Katherine [1 ,2 ]
Politei, Juan [3 ]
Banikazemi, Maryam [4 ,5 ]
Lee, Philip [6 ]
机构
[1] Massachusetts Gen Hosp, Ctr Human Genet Res, Richard B Simches Res Ctr, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
[3] Juan Fernandez Hosp, Neurol Serv, Buenos Aires, DF, Argentina
[4] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA
[5] Columbia Univ, Coll Phys & Surg, Dept Pediat, New York, NY USA
[6] Natl Hosp Neurol & Neurosurg, Charles Dent Metab Unit, London WC1N 3BG, England
关键词
Fabry disease; cerebrovascular accident; stroke; registries; ENZYME REPLACEMENT THERAPY; AGALSIDASE-BETA THERAPY; ALPHA-GALACTOSIDASE; CEREBROVASCULAR COMPLICATIONS; CEREBRAL HYPERPERFUSION; CRYPTOGENIC STROKE; MANIFESTATIONS; SAFETY; TRIAL; PREVALENCE;
D O I
10.1161/STROKEAHA.108.526293
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Stroke is a common and serious clinical manifestation of Fabry disease, an X-linked lysosomal storage disorder caused by deficiency of alpha-galactosidase A activity. This study was undertaken to better understand the natural history of cerebrovascular manifestations of Fabry disease. Methods-Data from 2446 patients in the Fabry Registry were analyzed to identify clinical characteristics of patients experiencing stroke during the natural history period (ie, before enzyme replacement therapy). Results-A total of 138 patients (86 of 1243 males [ 6.9%] and 52 of 1203 females [ 4.3%]) experienced strokes. Median age at first stroke was 39.0 years in males and 45.7 years in females. Most patients (70.9% of males and 76.9% of females) had not experienced renal or cardiac events before their first stroke. Fifty percent of males and 38.3% of females experienced their first stroke before being diagnosed with Fabry disease. Thirty patients (21 males and 9 females) had strokes at age <30 years. Most patients (86.8%) had ischemic strokes, but 16.9% of males and 6.9% of females had hemorrhagic strokes, among those for whom stroke type was reported. At the most recently available follow-up examination after their first stroke, 60% of males and 25.5% of females exhibited stage 3 to 5 chronic kidney disease and 66.1% of males and 59.5% of females had left ventricular hypertrophy. Conclusions-All patients with Fabry disease, regardless of age or gender, should be monitored for possible cerebrovascular complications, as stroke can occur in the absence of other key signs of the disease. (Stroke. 2009; 40: 788-794.)
引用
收藏
页码:788 / 794
页数:7
相关论文
共 33 条
[1]   Voxel based analyses of diffusion tensor imaging in Fabry disease [J].
Albrecht, J. ;
Dellani, P. R. ;
Mueller, M. J. ;
Schermuly, I. ;
Beck, M. ;
Stoeter, P. ;
Gerhard, A. ;
Fellgiebel, A. .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2007, 78 (09) :964-969
[2]   Agalsidase-beta therapy for advanced Fabry disease - A randomized trial [J].
Banikazemi, Maryam ;
Bultas, Jan ;
Waldek, Stephen ;
Wilcox, William R. ;
Whitley, Chester B. ;
McDonald, Marie ;
Finkel, Richard ;
Packman, Seymour ;
Bichet, Daniel G. ;
Warnock, David G. ;
Desnick, Robert J. .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (02) :77-86
[3]   Natural history of Fabry renal disease -: Influence of α-galactosidase A activity and genetic mutations on clinical course [J].
Branton, MH ;
Schiffmann, R ;
Sabnis, SG ;
Murray, GJ ;
Quirk, JM ;
Altarescu, G ;
Goldfarb, L ;
Brady, RO ;
Balow, JE ;
Austin, HA ;
Kopp, JB .
MEDICINE, 2002, 81 (02) :122-138
[4]   Middelheim Fabry Study (MiFaS): A retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke [J].
Brouns, Raf ;
Sheorajpanday, Rishi ;
Braxel, Ellen ;
Eyskens, Francois ;
Baker, Robert ;
Hughes, Derralynn ;
Mehta, Atul ;
Timmerman, Therese ;
Vincent, Marie-Francoise ;
De Deyn, Peter Paul .
CLINICAL NEUROLOGY AND NEUROSURGERY, 2007, 109 (06) :479-484
[5]   Radiological evidence of early cerebral microvascular disease in young children with Fabry disease [J].
Cabrera-Salazar, MA ;
O'Rourke, E ;
Charria-Ortiz, G ;
Barranger, JA .
JOURNAL OF PEDIATRICS, 2005, 147 (01) :102-105
[6]   Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years [J].
Carandang, Raphael ;
Seshadri, Sudha ;
Beiser, Alexa ;
Kelly-Hayes, Margaret ;
Kase, Carlos S. ;
Kannel, William B. ;
Wolf, Philip A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2939-2946
[7]  
DeGraba T, 2000, ANN NEUROL, V47, P229, DOI 10.1002/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO
[8]  
2-T
[9]  
Desnick RobertJ., 2001, The Metabolic and Molecular Bases of Inherited Disease, V8th, P3733
[10]   A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies [J].
Eng, CM ;
Banikazemi, M ;
Gordon, RE ;
Goldman, M ;
Phelps, R ;
Kim, L ;
Gass, A ;
Winston, J ;
Dikman, S ;
Fallon, JT ;
Brodie, S ;
Stacy, CB ;
Mehta, D ;
Parsons, R ;
Norton, K ;
O'Callaghan, M ;
Desnick, RJ .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (03) :711-722